Approval of the Audited Standalone Financial Results and Audited Standalone Financial Statements

WELCURE DRUGS AND PHARMACEUTICALS LIMITED CIN: L68100DL1996PLC227773 Registered Office: Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi, Delhi, India, 110092 Email: welcuredrugs227@gmail.com; Website: h(cid:425)ps://welcure.co.in/ Date- 31.10.2026 The General Manager, Corporate Relationship Department, BSE Limited, Phiroz Jeejeebhoy Tower, Dalal Street, Mumbai — 400001, Maharashtra, India Reference: ISIN: INE331C01025; Scrip Code: 524661; Symbol: WELCURE Subject: Outcome of the Meeting of the Board of Directors held on October 31, 2026 Dear Sir/Madam, Pursuant to Regulations 30 and 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on October 31, 2026, has inter alia approved the Audited Standalone Financial Results and Audited Standalone Financial Statements of the Company for the quarter and year ended March 31, 2026. This is in continuation of our earlier intimation dated May 29, 2026. Certain inadvertent errors were noticed in the figures of the Audited Standalone Financial Results and Audited Standalone Financial Statements submitted on May 29, 2026, and these have been corrected. The Audited Standalone Financial Results and Audited Standalone Financial Statements approved today, along with the other documents submitted herewith, supersede those submitted on May 29, 2026. The meeting commenced at 4:00 PM and concluded at 5:00 PM. You are requested to take the same on record. Thanking you, Yours Faithfully, FOR WELCURE DRUGS AND PHARMACEUTICALS LIMITED CHINTAN DIDAWALA GANPAT MANGING DIRECTOR & CFO DIN: 11088268 WELCURE DRUGS AND PHARMACEUTICALS LIMITED CIN:L68100DL1996PLC227773 Regd. Off. : Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Dehli - 110092 Website : www.welcuredrugs.com Email: welcuredrugs227@gmail.com STATEMENT OF AUDITED FINANCIAL RESULT FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026 (Rs in Lacs) Quarter Ended For The year ended Particulars 31.03.2026 31.12.2025 31.03.2025 31.03.2026 31.03.2025 (Audited) (Un-Audited) (Audited) (Audited) (Audited) Income: Revenue from Operations - - 2 ,121.10 3 8,952.44 2 ,455.00 Other income - 146.43 1 91.10 146.43 190.99 Total income (A) - 146.43 2,312.19 3 9,098.87 2,645.99 Expenses: Cost of materials consumed - - Purchases of stock-in-trade 14,762.40 3 4,635.31 16,402.70 Operation and maintenance expenses - - - Changes in Inventories - - ( 12,990.90) - (14,352.36) Purchase & Direct Expenses - - - - - Employee benefit expense - 1 .94 25.00 1 2.33 27.65 Finance costs - - - - - Depreciation & Amortization expenses - 0 .50 0.60 1.92 0 .76 Other expenses 5 ,003.73 1 .44 2 61.00 5,016.39 289.23 Total expenses (B) 5,003.73 3 .87 2,058.10 3 9,665.95 2,367.98 Profit before tax for the year (C) = (A-B) ( 5,003.73) 142.56 2 54.09 ( 567.08) 2 78.01 Tax expense: (i) Current tax - 3 5.88 - - 61.00 (ii) Deferred Tax Expenses - - - - - Total tax expense (D) - 35.88 - - 61.00 Other comprhensive Income (after Tax) A) Items that will not be reclassified to profit and loss - Income Tax on above - B) Items that will be reclassified to profit and loss - Income tax on above - Total Other Comprehensive Income (Net of Tax) - - - - - Total Comprehensive Income for the period comprising Net ( 5,003.73) 106.68 2 54.09 ( 567.08) 2 17.01 Profit/ (Loss) for the period & Other Comprehensive Income Paid-up equity share capital (Face Value: Rs. 1/- each ) 12,359.40 1 2,359.40 1 ,125.12 1 2,359.40 1 ,125.12 Earnings per equity share (in ₹) Basic (0.40) 0 .01 0.33 ( 0.05) 0 .36 Diluted (0.40) 0 .01 0.33 ( 0.05) 0 .36 Note: 1. The above Audited financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meeting held on 29th May, 2026. 2. The Auditor of the Company has carried out a audit of the Financial Results for the Quarter ended 31st March,2026 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 205 and has expressed their unqualified opinion. 3. The Audited Standalone Financial Results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (IND AS 34), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange board of India (SEBI) under SEBI (LODR) Regulation 2015, as amended. 4. The figures for the previous period/year have been regrouped/reclassified, wherever necessary. 5. The company does not have any Subsidiaries, Joint Ventures or Associate Companies as on March 31,2026 For Welcure Drugs and Pharmaceuticals limited Chintan Didawala Ganpat Place: Delhi MD & CFO Date: 31/10/2026 DIN : 11088268 Welcure Drugs and Pharmaceuticals Limited CIN :L24232DL1996PLC227773 Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092 Website: www.welcuredrugs.com Email: welcuredrugs227@gmail.com Balance Sheet as at 31st March, 2026 (Rupees in Lacs) As at 31st As at 31st March, Particulars March,2026 2025 ASSETS Non-current assets Property Plant and Equipment 1.11 3.03 Other Intangible assets Financial Assets Investments 128.74 - Loans 15166.59 8472.96 Other Financial Assets Deferred tax assets (net) Non-current Tax Assets (Net) Other non-current assets 8.85 7.73 Current assets Inventories 14352.36 14352.36 Financial Assets Trade receivables 21333.94 1895.00 Cash and cash equivalents 14.83 12.83 Loans Other Financial Assets 0 1950.84 Other current assets 6.80 3.08 Total Assets 51013.23 26697.82 EQUITY AND LIABILITIES Equity Equity Share capital 12359.40 11243.91 Other Equity (2674.47) (989.56) LIABILITIES Non-current liabilities Financial Liabilities Borrowings 0 12319.89 Other Financial Liabilities Provisions Current liabilities Financial Liabilities Borrowings Trade Payables Total outstanding due of (A) Micro enterprises and small enterprises 0 2.81 (B) Creditors other than micro enterprises and 17775.20704 286.95 small enterprises Other Financial Liabilities 23490.41 3773.51 Other current liabilities 1.68 1.68 Provisions 61 0.93 Current Tax Liabilities (Net) 61.00 Total Equity and Liabilities 51013.23 26701.12 For and on behalf of the Board of Directors Chintan Didawala Date: 31.10.2026 MD & CFO Place: Delhi DIN: 11088268 WELCURE DRUGS & PHARMACEUTICALS LIMITED CIN: L68100DL1996PLC227773 Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092 Website: www.welcuredrugs.com Email: welcuredrugs227@gmail.com Cash Flow Statement for the year ended 31th March,2026 Rs in Lakhs Upto 31st March,2026 F.Y. 2024-25 Sr. No. Particulars Amount (In Rs.) Amount (In Rs.) Amount (In Rs.) Amount (In Rs.) A. Cash flow from Operating Activities Net Profit before taxation (567.08) 278.01 Adjustments for : Depreciation & Amortisation Exp. 1 .91 0 .76 Previous Year Taxes Written Off Prior Period Expense 0 .76 Operating Profit before working capital changes (565.17) 2 78.77 Adjustment for Inventory - (14,352.36) Trade receivable (19,440.94) ( 1,895.00) Long term loans and advances ( 6,653.17) ( 8,344.22) Other financial Assets 1 ,950.84 ( 1,950.84) Other Current Assets 5 .94 (2.06) Trade Payable 19,632.03 2 89.76 Other Non Current Assets 0 .29 - Other Financial Liability (12,319.89) 3 ,772.41 Increase in Short term provision ( 13.39) - Other Current Liability 17,534.21 6 95.92 0 .66 (22,481.65) Net Cash Flow from Operating Activities (A) 1 30.75 (22,202.88) B. Cash flow from investing Activities Purchase/ Sale of Fixed Assets - (1.70) Change in Investments - 1 28.74 (4.65) Net Cash Flow from Investing Activities (B) (128.74) (6.35) C. Cash Flow From Financing Activities Proceeds From Issue of Equity Capital - 9 ,900.00 Repayment of long term borrowing - Proceeds from long term borrowing 1 2,319.89 Net Cash Flow [Showing first 8,000 characters — download PDF for full document]